C12Y 401/01028
Aromatic-l-amino-acid decarboxylase , i.e. tryptophane-decarboxylase
Official title: Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
C12Y401/01028 (Aromatic-l-amino-acid decarboxylase , i.e. tryptophane-decarboxylase) appears on 39 US grants and 80 published applications in this corpus.
Search patents in C12Y- Granted patents
- 39
- Published applications
- 80
- Assignees
- 44
- Inventors
- 167
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 3 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 2 | 2 |
| 2017 | 0 | 5 |
| 2018 | 0 | 3 |
| 2019 | 3 | 12 |
| 2020 | 1 | 3 |
| 2021 | 7 | 9 |
| 2022 | 2 | 4 |
| 2023 | 1 | 10 |
| 2024 | 7 | 8 |
| 2025 | 5 | 7 |
| 2026 | 2 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Engineered tryptophan decarboxylases and uses thereof for synthesizing tryptamine analogs4 Aug 2026US 12,698,495 B2Wisconsin Alumni Research Foundation
- Recombinant AAV vectors for treating neurodegenerative disorders21 Apr 2026US 12,605,467 B2Shanghai Vitalgen Biopharma Co., Ltd.
- Recombinant AAV vectors useful for reducing immunity against transgene products11 Nov 2025US 12,467,063 B2University of Massachusetts
- Gene therapy for AADC deficiency9 Sep 2025US 12,409,235 B2National Taiwan University
- Recombinant Escherichia coli for producing glutarate, construction method and use thereof26 Aug 2025US 12,398,408 B2Jiangnan University
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Enzymes, polynucleotides encoding same, and methods of using same for producing tryptamines30 Jul 2026US 2026/0218257 A1Yeda Research and Development Co. Ltd.
- Methods for the Production of Tryptophan Derivatives23 Jul 2026US 2026/0209808 A1Natural MedTech Pty Ltd
- Recombinant aav vectors for treating neurodegenerative disorders16 Jul 2026US 2026/0199527 A1Shanghai Vitalgen Biopharma Co., Ltd.
- Recombinant aav vectors useful for reducing immunity against transgene products18 Jun 2026US 2026/0167990 A1University of Massachusetts
Most cited
By later US patents
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)108US 6,309,634 B1Avigen, Inc. · 2001
- Matrices for drug delivery and methods for making and using the same105US 6,395,299 B1Biostream, Inc. · 2002
- AAV-mediated delivery of DNA to cells of the nervous system81US 6,503,888 B1The Rockefeller University · 2003
- Methods of treating central nervous system disorders using viral vectors46US 6,953,575 B2Avigen, Inc. · 2005